Rona Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $200M
Overview
A clinical-stage biotech developing long-acting siRNA therapeutics for metabolic and degenerative diseases using proprietary liver and extrahepatic delivery platforms.
CardiovascularMetabolicNeurologicalHepatic
Technology Platform
Proprietary siRNA delivery platforms including GAIA for liver-targeted delivery using GalNAc conjugation and APOLLO for extrahepatic delivery to tissues like the CNS using small molecule conjugation.
Opportunities
Significant growth opportunity in expanding RNA therapeutics beyond liver to CNS and other tissues via their APOLLO platform, and addressing large metabolic disease markets with long-acting therapies that improve patient compliance.
Risk Factors
Clinical development risks for novel delivery platforms, particularly for extrahepatic targets; competitive intensity in metabolic disease therapeutics from both siRNA and other modality approaches; and execution risk as a relatively young company advancing multiple programs simultaneously.
Competitive Landscape
Competes with Alnylam and other RNA therapeutics companies in metabolic diseases; differentiation through proprietary extrahepatic delivery technology and focus on ultra-long-acting dosing intervals (up to 9 months or longer) for improved patient compliance.